Peptide Half-Lives Explained

Understanding pharmacological half-life in peptide research — how molecular structure, modifications, and administration route affect duration of action and dosing frequency.

What Is Half-Life?

In pharmacology, half-life (t½) refers to the time required for the concentration of a substance in the body to decrease by 50%. After one half-life, 50% of the original dose remains active; after two half-lives, 25%; after three, 12.5%. As a general rule, a peptide is considered effectively cleared after approximately 4–5 half-lives.

Half-life directly determines dosing frequency. A peptide with a 10-minute half-life requires frequent or continuous administration to maintain therapeutic levels, while one with a multi-day half-life may only need weekly dosing. Understanding these kinetics is fundamental to designing rational research protocols.

Factors That Influence Peptide Half-Life

Molecular Size and Structure

Smaller peptides (fewer than 10 amino acids) are typically cleared rapidly through renal filtration and enzymatic degradation. Larger peptides and those with complex tertiary structures tend to resist proteolytic breakdown and have longer circulation times. Cyclic peptides, for example, are more resistant to exopeptidases than their linear counterparts Craik et al., 2013.

PEGylation

Attaching polyethylene glycol (PEG) chains to peptides — a process called PEGylation — increases molecular size, reduces renal clearance, and shields the peptide from enzymatic degradation. PEG-MGF is a classic example: native MGF has a half-life of minutes, while PEGylation extends this substantially Veronese & Mero, 2008.

Drug Affinity Complex (DAC)

The Drug Affinity Complex is a modification that allows a peptide to bind to serum albumin after injection, dramatically extending half-life. The most well-known example is CJC-1295 — without DAC, it has a half-life of roughly 30 minutes, but with DAC technology, the half-life extends to approximately 8 days Teichman et al., 2006.

Amino Acid Modifications

D-amino acid substitution: Replacing L-amino acids with their D-enantiomers at cleavage sites protects against proteolysis
N-methylation: Methylation of backbone amides reduces enzymatic recognition
Acetylation and amidation: Capping the N- or C-terminus protects against exopeptidases
Fatty acid acylation: Used in semaglutide and liraglutide to promote albumin binding, extending half-life from minutes to days Lau et al., 2015

Route of Administration

The administration route significantly affects effective half-life and bioavailability. Subcutaneous injection creates a depot effect that slows absorption, while intranasal and topical routes often result in rapid local action with minimal systemic exposure.

Peptide Half-Life Reference Table

Peptide	Approximate Half-Life	Route	Key Notes
BPC-157	~4 hours	SC/Oral	Stable in gastric acid (arginate salt)
TB-500	~8 hours	SC	Thymosin beta-4 fragment
CJC-1295 (no DAC)	~30 minutes	SC	Rapid GHRH receptor activation
CJC-1295 (with DAC)	~8 days	SC	Albumin-binding extends duration
Ipamorelin	~2 hours	SC	Selective GHS-R agonist
Sermorelin	~10–20 minutes	SC	Short-acting GHRH analog
MK-677	~5 hours	Oral	Non-peptide GHS-R agonist
Semaglutide	~7 days	SC/Oral	Fatty acid acylation + albumin binding
GHK-Cu	Minutes	Topical	Rapid local action, minimal systemic
Epithalon	Minutes (IV/SC)	SC/IV	Short-acting telomerase activator
DSIP	~7 minutes	IV	Delta sleep-inducing peptide
Semax	Minutes	Intranasal	Rapid CNS penetration
PT-141	~2 hours	SC	Melanocortin receptor agonist
GHRP-6	~20–30 minutes	SC	Potent but non-selective GHS-R agonist
GHRP-2	~25–30 minutes	SC	More selective than GHRP-6
Tirzepatide	~5 days	SC	Dual GIP/GLP-1 receptor agonist
Tesamorelin	~26–38 minutes	SC	FDA-approved GHRH analog

Dosing Implications

Short Half-Life Peptides (minutes to <1 hour)

Peptides like Sermorelin, GHRP-2, and GHRP-6 require multiple daily administrations to maintain pulsatile GH release patterns. This aligns with the natural physiology of GH secretion, which occurs in pulses rather than continuous release Veldhuis et al., 1991.

Medium Half-Life Peptides (1–8 hours)

Peptides such as Ipamorelin, BPC-157, and MK-677 allow for once or twice daily dosing. MK-677's oral bioavailability and ~5-hour half-life make it particularly convenient, though its effects on IGF-1 levels persist for up to 24 hours due to downstream signaling Nass et al., 2008.

Long Half-Life Peptides (days)

Semaglutide (~7 days) and CJC-1295 with DAC (~8 days) enable weekly dosing. These extended half-lives are achieved through deliberate molecular engineering — fatty acid acylation for semaglutide and albumin-binding DAC technology for CJC-1295. The convenience of weekly dosing has been a major factor in the clinical success of GLP-1 receptor agonists Marbury et al., 2017.

Steady-State Considerations

With repeated dosing, peptide concentrations accumulate until reaching steady state — the point at which drug intake equals elimination per dosing interval. Steady state is typically reached after 4–5 half-lives of consistent dosing. For CJC-1295 with DAC, this means steady state is not reached until approximately 5–6 weeks of weekly dosing, which has implications for both efficacy assessment and cycling protocols.

Key Principle: A peptide's half-life is not the same as its duration of biological effect. Downstream signaling cascades, receptor binding kinetics, and tissue-level effects can persist well beyond the plasma half-life of the parent compound. IGF-1 elevation from GH secretagogues, for instance, may remain elevated for 24+ hours even when the peptide itself has been cleared.